Patent details

301277 Product Name: dolutegravir of een farmaceutisch aanvaardbaar zout, waaronder dolutegravirnatrium, en lamivudine

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301277
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP3494972
Status:
Application Pending
Application number:
301277
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)

Marketing Authorization

Marketing Authorization Number:
EU/1/19/1370
Marketing Authorization Type:
EEA
Marketing Authorization Date:
03/07/2019
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
03/06/2024
First Marketing Authorization date:
03/07/2019
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
04/06/2024
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
03/06/2024
 
 

 

Name:
VIIV Healthcare Company
Address:
251 Little Falls Drive, 19808, Wilmington, DE , United States of America (US)

Agent

Name:
ir. J.C. Volmer c.s.
From:
03/06/2024
Address:
Exter Polak & Charlouis B.V. Postbus 3241, 2280 GE, Rijswijk, Netherlands (NL)
To:

Publication

Bulletin

Bulletin Heading:
SPC
Journal edition number:
23/24
Publication date:
05/06/2024
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
24/09/2025 Outgoing Correspondence Letter to applicant 1 PDF /6/8/4/6/0/0801006486/docs/301277_11_301277675486l173.pdf
16/09/2025 Incoming Correspondence Electronic Accompanying letter incoming document 1 PDF /6/8/4/6/0/0801006486/docs/301277_10_incomingcorrespondenceelectronic20250917085223560.pdf
24/07/2025 Outgoing Correspondence Letter to applicant 5 PDF /6/8/4/6/0/0801006486/docs/301277_9_301277666526l173.pdf
04/06/2024 Outgoing Correspondence Confirmation receipt request 2 PDF /6/8/4/6/0/0801006486/docs/301277_0_606424l174.pdf
04/06/2024 SPC Documents Annex SPC 20 PDF /6/8/4/6/0/0801006486/docs/301277_5_supplprotectioncertificate20240604121003103.pdf
04/06/2024 SPC Documents Annex SPC 2 PDF /6/8/4/6/0/0801006486/docs/301277_6_supplprotectioncertificate20240604121003084.pdf
03/06/2024 SPC Documents Accompanying letter SPC 3 PDF /6/8/4/6/0/0801006486/docs/301277_1_supplprotectioncertificate20240604120504972.pdf
03/06/2024 SPC Documents Annex SPC 16 PDF /6/8/4/6/0/0801006486/docs/301277_2_supplprotectioncertificate20240604120521784.pdf
03/06/2024 SPC Documents Marketing Authorization SPC 3 PDF /6/8/4/6/0/0801006486/docs/301277_3_supplprotectioncertificate20240604120545706.pdf
03/06/2024 SPC Documents Summary of the characteristics of the product 24 PDF /6/8/4/6/0/0801006486/docs/301277_4_supplprotectioncertificate20240604121003061.pdf
03/06/2024 SPC Documents Annex SPC 52 PDF /6/8/4/6/0/0801006486/docs/301277_7_supplprotectioncertificate20240604121039343.pdf
03/06/2024 Application Form First filed application form 2 PDF /6/8/4/6/0/0801006486/docs/301277_8_applicationform20240604121418436.pdf